Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=399 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
N/A N=800 A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
N/A N=362 A Study in Adolescent Females to Explore Cytomegalovirus Infection
Infections, Cytomegalovirus
Primary: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum. — 5; 2 Participants
Phase 3 N=96 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Phase 2 N=10 Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants
N/A N=14 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Phase 4 N=78 The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
N/A N=155 Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus
Infections, Cytomegalovirus · Cytomegalovirus Infections
Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants
Phase 1 N=128 Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
Cytomegalovirus Infections
Primary: Number of Participants With Local and Systemic Adverse Events During Seven-Day Follow-Up Period — 11; 14; 13; 5 Participants
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Phase 2 N=35 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
Phase 2 N=61 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Phase 3 N=452 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Phase 2 N=58 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
Phase 2 N=239 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
Phase 2 N=315 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Cytomegalovirus Infection
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 33; 59; 40; 12 Participants
Phase 4 N=205 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
Cytomegalovirus Infection
Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396
Phase 2 N=77 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
Phase 2 N=61 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Cumulative Incidence of CMV at 100 Days — 25.1; 13.8 cases per 100 persons
N/A N=111 Evaluation of the Artus® CMV PCR Test
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
Phase 1 N=190 Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Cytomegalovirus Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 75.0; 92.9; 84.6; 100.0 Percentage of participants
Phase 3 N=601 Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
CMV Disease
Primary: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant — 10.4; 11.8 Percentage of Participants
Phase 1 N=11 Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Phase 4 N=57 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Kidney Transplantation, Cytomegalovirus Infections
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Withdrawal Due to AEs — 56; 41; 6 Participants
N/A N=172 Dried Blood Spot Testing of CMV Detection in HCT Recipients
Cytomegalovirus Infection
Primary: The Number of Participants Who Have Completed >90% of Their Recommended Cytomegalovirus (CMV) Monitoring Tests in the DBS and Control Arms in the ITT Population — 27; 15…
Phase 2 N=38 Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants